News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|May 6, 2024

Apolipoprotein E4 in Alzheimer’s Disease

Author(s)Richard Isaacson, MD, Sharon Cohen, MD, FRCPC, Marwan Sabbagh, MD

Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.

Episodes in this series

EP. 1 Apolipoprotein E4 in Alzheimer’s Disease

EP. 1 Apolipoprotein E4 in Alzheimer’s Disease

EP. 2 Importance of Early Diagnosis of Alzheimer’s Disease

EP. 2 Importance of Early Diagnosis of Alzheimer’s Disease

Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"

EP. 3 Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"

EP. 4 Amyloid Cascade Hypothesis of Alzheimer’s Disease

Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"

EP. 5 Contribution of Multiple Pathways to the Development of Alzheimer’s Disease

Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"

EP. 6 Utilization of Neuroimaging in Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 7 CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 8 Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 9 Alzheimer’s Disease Pipeline

A panel of 3 experts on Alzheimer's disease

EP. 10 The Future Outlook for Alzheimer’s Disease

Video content above is prompted by the following question(s):

How are different stages of Alzheimer’s disease (AD; preclinical AD, prodromal AD, and AD with dementia) defined?
1. What are known risk factors for Alzheimer's disease?
  1. Contribution of ApoE gene polymorphism and copy numbers
2. When do patients with Alzheimer’s typically present to the clinic?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission

November 27th 2025

Talya Fleming, MD

Understanding the Barriers of Health Insurance in Stroke Rehabilitation Care

ByTalya Fleming, MD,Louie Pasculli

November 27th 2025

Enna Selmanovic

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development

ByEnna Selmanovic,Louie Pasculli

November 27th 2025

Shae Datta, MD

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients

ByLouie Pasculli,Shae Datta, MD

November 26th 2025

stacy Finkbeiner

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea

ByLouie Pasculli

November 26th 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission

Understanding the Barriers of Health Insurance in Stroke Rehabilitation Care

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials

© 2025 MJH Life Sciences^®

All rights reserved.